Ticlopidine Hydrochloride

Sold as Ticlid. Every FDA application for this active ingredient: 1 branded and 9 generic.

As of Nov 15, 2026, FDA lists 10 applications for Ticlopidine Hydrochloride (sold as Ticlid), first approved Oct 31, 1991, with 1 new use approved and 0 published complete response letters.

First approved: Oct 31, 1991
Applications: 10
New uses approved: 1
Complete response letters: 0

Clinical Trials

81 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial StenosisIschemic Stroke, Symptomatic Intracranial Atherosclerotic Stenosis · Second Affiliated Hospital of Soochow University	Phase 4	Recruiting	Nov 12, 2026
Prevalence of CYP2C19 Genetic Polymorphisms Among Egyptian Patients Receiving Clopidogrel Following PCIAcute Coronary Syndrome · October 6 University	—	Enrolling by invitation	Oct 15, 2026
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCICoronary Artery Disease, Acute Coronary Syndromes · Jilin University	Not applicable	Recruiting	Sep 29, 2026
Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)Acute Ischemic Stroke · University of Alberta	Phase 2	Not yet recruiting	Sep 28, 2026
Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban TherapyCardiac Event, Coronary Artery Disease · Seoul National University Bundang Hospital	Phase 4	Recruiting	Sep 1, 2026
A Clinical Trial of Antiplatelets in PsoriasisPsoriasis (PsO), Psoriatic Arthritis (PsA) · NYU Langone Health	Phase 4	Not yet recruiting	Aug 4, 2026
A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet TherapyCardiovascular Prevention · François MACH	Not applicable	Not yet recruiting	Jul 22, 2026
Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) TrialSCAD, ACS (Acute Coronary Syndrome) · Universitätsklinikum Hamburg-Eppendorf	Phase 4	Not yet recruiting	Jul 6, 2026

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Oct 31, 1991	TiclidNDA 19979 · New molecular entity	Roche Palo	15	Discontinued
Jul 1, 1999	Ticlopidine HydrochlorideANDA 75089	Apotex	7	Discontinued
Aug 20, 1999	Ticlopidine HydrochlorideANDA 75149	Teva	4	Discontinued
Aug 20, 1999	Ticlopidine HydrochlorideANDA 75253	Actavis Elizabeth	7	Discontinued
Aug 20, 1999	Ticlopidine HydrochlorideANDA 75318	Chartwell Rx	0	Discontinued
Aug 20, 1999	Ticlopidine HydrochlorideANDA 75326	Chartwell Rx	4	Discontinued
Sep 13, 1999	Ticlopidine HydrochlorideANDA 75161	Mylan	5	Discontinued
Nov 2, 1999	Ticlopidine HydrochlorideANDA 75316	Natco Pharma	0	Discontinued
Apr 26, 2000	Ticlopidine HydrochlorideANDA 75309	Watson Labs	0	Discontinued
Sep 26, 2002	Ticlopidine HydrochlorideANDA 75526	Sun Pharm Inds Inc	2	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA